355387-56-3

Upstream product

• 705257-43-8 4-allyl-2-propyl-benzene-1,3-diol 
• 705257-21-2 3-allyloxy-2-propyl-phenol 
• 13331-19-6 2-propyl-1,3-benzenediol 
• 108-46-3 recorcinol 
• 13594-95-1 1,3-bis(allyloxy)benzene 
• 71489-64-0 2,4-diallyl-1,3-benzenediol 
• 355387-55-2 1-(2,4-dihydroxy-3,5-dipropylphenyl)-2,2,2-trifluoroethanone 

Downstream Products

• 449780-14-7 (5,7-dipropyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-[4-(pyridin-2-ylmethoxy)-phenyl]-acetic acid methyl ester 
• 449779-52-6 (5,7-dipropyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-(4-isopropyl-phenyl)-acetic acid methyl ester 
• 449779-50-4 (4-chloro-phenyl)-(5,7-dipropyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-acetic acid methyl ester 
• 449779-49-1 (5,7-dipropyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-phenyl-acetic acid methyl ester 

Relevant academic research and scientific papers

Discovery of a novel series of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes and dyslipidemia

A series of 2-aryloxy-2-methyl-propionic acid compounds and related analogues were designed, synthesized, and evaluated for their PPAR agonist activities. 2-[(5,7-Dipropyl-3-trifluoromethyl)-benzisoxazol-6-yloxy]-2- methylpropionic acid (4) was identified

O-Arylmandelic acids as highly selective human PPAR α/γ agonists

A new class of O-arylmandelic acid PPAR agonists show excellent anti-hyperglycemic efficacy in a db/db mouse model of DM2. These PPARα-weighted agonists do not show the typical PPARγ associated side effects of BAT proliferation and cardiac hypertrophy in